MarketCap
Facebook
X
TelegramQuarterly report 2022-Q3
added 11-10-2022
Otonomy Total Shareholders Equity 2011-2026 | OTIC
Annual Total Shareholders Equity Otonomy
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 54.9 M | 66.3 M | 40.2 M | 79.7 M | 117 M | 193 M | 182 M | 154 M | -59 M | -39.1 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 193 M | -59 M | 78.8 M |
Quarterly Total Shareholders Equity Otonomy
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 21.4 M | - | 43.2 M | 54.9 M | 66.5 M | 77.7 M | 56 M | 66.3 M | 66.3 M | 66.3 M | 66.3 M | 40.2 M | 40.2 M | 40.2 M | 40.2 M | 79.7 M | 79.7 M | 79.7 M | 79.7 M | 117 M | 117 M | 117 M | 117 M | 193 M | 193 M | 193 M | 193 M | 182 M | 182 M | 182 M | 182 M | 154 M | 154 M | 154 M | 154 M | -59 M | -59 M | - | - | -39.1 M | - | - | - | -30.9 M | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 193 M | -59 M | 91 M |
Total Shareholders Equity of other stocks in the Biotechnology industry
| Issuer | Total Shareholders Equity | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
621 M | - | 2.43 % | $ 254 M |  Germany |
 |
AgeX Therapeutics
AGE
|
-37 K | - | -10.17 % | $ 12.2 K |  USA |
 |
I-Mab
IMAB
|
1.72 B | - | - | $ 866 M |  China |
 |
Exelixis
EXEL
|
2.16 B | $ 48.43 | 9.03 % | $ 13.2 B | USA |
 |
Fortress Biotech
FBIO
|
49.9 M | $ 2.56 | 3.96 % | $ 71.4 M | USA |
 |
Midatech Pharma plc
MTP
|
6.72 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Galapagos NV
GLPG
|
2.67 B | $ 28.78 | 1.36 % | $ 2.69 B |  Belgium |
 |
Biophytis SA
BPTS
|
2.27 M | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
-16.2 M | - | 2.54 % | $ 160 B | France |
 |
Genmab A/S
GMAB
|
14 B | $ 27.93 | 1.41 % | $ 17.2 B |  Danmark |
 |
Genprex
GNPX
|
7.96 M | $ 0.9 | 2.02 % | $ 839 K | USA |
 |
Grifols, S.A.
GRFS
|
6.72 B | $ 8.41 | 1.69 % | $ 6.83 B |  Spain |
 |
Athira Pharma
ATHA
|
27.8 M | - | - | $ 269 M | USA |
 |
InflaRx N.V.
IFRX
|
77.9 M | $ 2.47 | 25.39 % | $ 152 M | Germany |
 |
Ionis Pharmaceuticals
IONS
|
489 M | $ 76.96 | 2.27 % | $ 12.3 B | USA |
 |
Kamada Ltd.
KMDA
|
179 M | $ 8.3 | 1.1 % | $ 260 M |  Israel |
 |
BioNTech SE
BNTX
|
1.37 B | $ 95.07 | -0.45 % | $ 27.2 B | Germany |
 |
Kymera Therapeutics
KYMR
|
1.58 B | $ 86.14 | 4.15 % | $ 7.28 B | USA |
 |
Checkmate Pharmaceuticals
CMPI
|
69.5 M | - | - | $ 231 M | USA |
 |
Ligand Pharmaceuticals Incorporated
LGND
|
830 M | $ 229.83 | -1.06 % | $ 4.2 B | USA |
 |
INmune Bio
INMB
|
23.5 M | $ 1.52 | -1.3 % | $ 37.6 M | USA |
 |
Liquidia Corporation
LQDA
|
44.7 M | $ 41.84 | 4.26 % | $ 3.6 B | USA |
 |
Mirum Pharmaceuticals
MIRM
|
315 M | $ 107.42 | 1.52 % | $ 5.39 B | USA |
 |
ACADIA Pharmaceuticals
ACAD
|
733 M | $ 22.32 | -0.13 % | $ 3.7 B | USA |
 |
MannKind Corporation
MNKD
|
-51 M | $ 3.68 | 28.5 % | $ 1.12 B | USA |
 |
Advaxis
ADXS
|
-24.4 M | - | -9.65 % | $ 45.9 M | USA |
 |
Nanobiotix S.A.
NBTX
|
70.5 M | $ 42.28 | 21.6 % | $ 286 B | France |
 |
Esperion Therapeutics
ESPR
|
-302 M | $ 3.13 | 0.55 % | $ 651 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
5.59 M | $ 3.47 | -8.44 % | $ 5.71 M | Israel |
 |
Aeglea BioTherapeutics
AGLE
|
715 M | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
688 M | - | - | $ 867 M | Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
29.5 M | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
69.4 M | - | 1.93 % | $ 17.4 M | USA |
 |
Akero Therapeutics
AKRO
|
750 M | - | - | $ 3.67 B | USA |
 |
Aptose Biosciences
APTO
|
-27.2 M | - | -45.71 % | $ 1.2 M |  Canada |
 |
Aptinyx
APTX
|
38.3 M | - | -39.0 % | $ 4.57 M | USA |
 |
Akouos
AKUS
|
234 M | - | 0.23 % | $ 488 M | USA |
 |
Albireo Pharma
ALBO
|
176 M | - | -0.23 % | $ 916 M | USA |
 |
Allakos
ALLK
|
169 M | - | - | $ 28.6 M | USA |
 |
AlloVir
ALVR
|
78.8 M | - | 4.14 % | $ 49.1 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
189 M | $ 23.86 | 1.88 % | $ 3.04 B | USA |
 |
Allena Pharmaceuticals
ALNA
|
18.9 M | - | 3.16 % | $ 1.9 M | USA |
 |
Puma Biotechnology
PBYI
|
130 M | $ 7.5 | 2.04 % | $ 375 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
3.36 M | - | -11.43 % | $ 502 K | USA |
 |
Applied Molecular Transport
AMTI
|
60.8 M | - | - | $ 10.1 M | USA |
 |
Alpine Immune Sciences
ALPN
|
179 M | - | - | $ 2.17 B | USA |